Clinical Trials
599
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (336 trials with phase data)• Click on a phase to view related trials
INTERACT Stomach-II
- Conditions
- Peritoneal Metastases From Gastric Cancer
- Interventions
- Drug: intraperitoneal chemotherapy
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT07133490
Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI
- Conditions
- Glioblastoma
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT07121842
- Locations
- 🇳🇱
Amsterdam UMC, Amsterdam, Netherlands
🇳🇱Leiden UMC, Leiden, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
Lycopene as a Dietary Compliance Biomarker
- Conditions
- Healthy
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT07117110
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
- Conditions
- Solid CancerGastric (Cardia, Body) CancerEsophageal CancerColorectal Cancer (CRC)
- Interventions
- Drug: Blood sampling for pharmacokinetics
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 66
- Registration Number
- NCT07114627
- Locations
- 🇳🇱
Erasmus MC Cancer Institute, Rotterdam, Netherlands
Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli
- Conditions
- Carriage of ESBL-positive Escherichia ColiCarriage of ESBL-positive Klebsiella Pneumoniae
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT07106944
- Prev
- 1
- 2
- 3
- 4
- 5
- 88
- Next
News
AIM ImmunoTech Reports Promising Mid-Year Results from Phase 2 Pancreatic Cancer Combination Therapy Study
AIM ImmunoTech's Phase 2 DURIPANC study evaluating Ampligen combined with AstraZeneca's Imfinzi shows encouraging safety and efficacy signals in metastatic pancreatic cancer patients post-FOLFIRINOX treatment.
Egetis Therapeutics Advances Toward US NDA Submission for Tiratricol Following FDA Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy Designation to Egetis Therapeutics' tiratricol in July 2025 for treating MCT8 deficiency, based on survival data showing significant improvement in treated versus untreated patients.
€26.2 Million GREG Initiative Launches to Transform Real-World Evidence Practices Across Europe
The GREG initiative, a five-year €26.2 million public-private partnership, has launched to advance Real-World Evidence practices for medicines and medical devices evaluation across Europe.
Socioeconomic Factors and Parental Smoking Linked to Worse MS Outcomes in Children
Children from socioeconomically disadvantaged backgrounds show more severe brain inflammation and tissue loss when diagnosed with multiple sclerosis, according to a new study published in Neurology.
AIM ImmunoTech Advances to Phase 2 Trial of Ampligen-Imfinzi Combination for Late-Stage Pancreatic Cancer
Safety Committee grants approval for Phase 2 portion of AIM ImmunoTech's Phase 1b/2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment.